Abstract
In the coming years, asthma therapy should be tailored to the individual patient's needs. The principles of optimal asthma control and symptom-driven therapy offer the possibility for more individualised asthma management. Omalizumab (monoclonal anti IgE) may have positive clinical effects, including a reduction in the exacerbation-rate, and is indicated for patients, who--in spite of best possible asthma therapy--continue to have reduced lung function, severe exacerbations, severe symptoms, and documented non-seasonal allergy.
| Translated title of the contribution | New principles and possibilities in the treatment of asthma |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 169 |
| Issue number | 11 |
| Pages (from-to) | 995-7 |
| Number of pages | 3 |
| ISSN | 0041-5782 |
| Publication status | Published - 2007 |